India Pharma Sees High Employee Attrition, Talent Shortage
This article was originally published in PharmAsia News
Executive Summary
India's pharmaceutical industry has employee-attrition levels of about 30 percent, leading to staffing concerns among drug makers. Pfizer India Managing Director Kewal Handa says the attrition is due largely to poaching by companies from other industries such as financial institutions and insurance firms. Novartis Managing Director Ranjit Shahani said his company also had a shortage of talent, even at the middle levels of the firm. Novartis said its attrition rate is about 10 percent, and Pfizer says its is about 20 percent in India. (Click here for more
You may also be interested in...
Keeping Track: Cancer Approvals From Lumisight Imaging To Adjuvant Alecensa
The US FDA’s approval of Lumicell’s optical imaging agent Lumisight makes a dozen novel approvals in 2024 for the Center for Drug Evaluation and Research.
Partisan Politics Returns To US FDA Congressional Oversight
The US FDA has stood out as an agency that tends to draw broad bipartisan support amid a generally rancorous and divided Congress. A House hearing, however, may be a sign that those days are over.
GLP-1 Coverage Restrictions In Medicare Part D Surge As Demand For Obesity Drugs Grows
A major shift from unfettered coverage to prior authorizations was recorded by MMIT over the past year for the leading GLP-1/GIP agonist diabetes drugs. Public interest in using the drugs off label for weight loss drove the change.